Physician profile
Regina Strand
NPI 1093739310
$2,549.46
in general payments reported to CMS, 2019-2025
18 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $92.01 · 2021: $210 · 2022: $325 · 2023: $434 · 2024: $593 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $504.37 | 2019-2025 | Acuvue |
| Ocular Therapeutix, INC. | $258.33 | 2024 | Dextenza |
| Oyster Point Pharma, INC. | $249.22 | 2022-2024 | Tyrvaya |
| Hoffmann-La Roche Limited | $197.34 | 2019 | |
| Coopervision INC. | $188.58 | 2019-2024 | Clariti Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $175.47 | 2019-2025 | Total30, Precision7 |
| Allergan, INC. | $155.97 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $155.90 | 2021-2023 | Cequa |
| Novartis Pharmaceuticals Corporation | $137.75 | 2019-2022 | |
| Biotissue Holdings INC. | $125.00 | 2023 | |
| Bausch & Lomb Americas INC. | $101.84 | 2024 | Xiidra, Miebo |
| Celularity INC. | $100.61 | 2021 | |
| Dompe US, INC. | $60.28 | 2025 | Oxervate |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $38.05 | 2024-2025 | Xdemvy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lombart Brothers, INC. | $24.70 | 2019 | |
| Abbvie INC. | $20.80 | 2024 | |
| Plexus Optix, INC. | $16.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Strand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.